Stereotaxis to Present at Upcoming Investor Conferences


ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, chairman and CEO, will present at three investor conferences in the first quarter 2022.

  • Aegis Capital Corp. Virtual Conference
    Mr. Fischel will present an overview of Stereotaxis business on Friday, February 25th, 2022, at 12:00 pm EST and will be available that day for one-on-one meetings.

“We appreciate the invitations to these conferences and look forward to sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with the investment community,” says Mr. Fischel. One-on-one meetings with Mr. Fischel can be arranged through registration with these conferences.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
investors@stereotaxis.com